Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pirker, R.
Right arrow Articles by Huber, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pirker, R.
Right arrow Articles by Huber, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S71-S76, 1999
© 1999 European Society for Medical Oncology

Reviews

Adjuvant and induction chemotherapy in non-small cell lung cancer

R. Pirker, R. Malayeri and H. Huber

Division of Oncology, Department of Internal Medicine I, University of Vienna Vienna, Austria

Correspondence to: Prof. Dr. Robert Pirker Division of Oncology, Department of Internal Medicine I, Währinger Gurtel 18, A-1090 Vienna, Austria e-mail: robert.pirker1{at}akh-wien.ac.at

About 25%–30% of patients with non-small cell lung cancer can be resected with curative intent. However, systemic relapses occur in up to 70% of these patients. Thus, postoperative adjuvant chemotherapy was evaluated in several randomised trials but the results of these trials were inconclusive with a survival benefit only in some trials. Shortcomings of these trials included low number of patients, poor patient compliance and inadequate chemotherapy protocols. A recent meta-analysis suggested an absolute survival benefit of 5% at five years for postoperative cisplatin-based chemotherapy as compared to surgery alone. Thus adjuvant chemotherapy with both improved chemotherapy protocols and improved anti-emetics is currently re-evaluated in several randomised trials on large patient populations.

Patients with locally advanced (stage III) non-small cell lung cancer require a multimodal approach with both local therapies (surgery, radiotherapy or both) and systemic chemotherapy. Patients with completely resected stage IIIA disease should be enrolled in randomised adjuvant chemotherapy trials with or without radiotherapy. Patients with clinically stage IIIA and selected patients with stage 1KB are candidates for induction chemotherapy followed by surgery. The remaining stage III patients should receive combined chemoradiotherapy.

adjuvant chemotherapy, induction chemotherapy, induction therapy, multimodality treatment, non-small cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.